Cell Biotech Co

Cell Biotech Co Net Debt/Equity

The Net Debt to Equity Ratio of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is -0.70. In the previous year, Net Debt to Equity Ratio was -0.62 — a change of 13.08% (lower).

Net Debt/Equity

-0.70

YoY

13.08%

Last updated:

Net Debt to Equity Ratio of Cell Biotech Co is 2024 -0.70 . Net Debt to Equity Ratio of Cell Biotech Co was 2023 -0.62 . It decreases by 13.08% lower compared to the previous year.

The Cell Biotech Co Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2017
-0.66 KRW
Jan 1, 2018
-0.59 KRW
Jan 1, 2019
-0.57 KRW
Jan 1, 2020
-0.54 KRW
Jan 1, 2021
-0.54 KRW
Jan 1, 2022
-0.60 KRW
Jan 1, 2023
-0.62 KRW
Jan 1, 2024
-0.70 KRW
The Cell Biotech Co Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.70+13.08%
-0.62+3.13%
-0.60+11.77%
-0.54-0.73%
-0.54-4.34%
-0.57-3.71%
-0.59-10.94%
-0.66-0.32%
-0.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Net Debt to Equity Ratio of Cell Biotech Co is -0.70 in 2024.

Net Debt to Equity Ratio of Cell Biotech Co changed from -0.62 to -0.70, representing a 13.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cell Biotech Co

All Key Metrics — Cell Biotech Co